The investigation centers on claims made by Hunterbrook, which alleged that Ensign’s profitability relies on understaffing facilities and manipulating quality metrics. According to the report, taxpayer funds were diverted to executives and affiliates, potentially at the expense of patient safety. These findings, released following a five-month investigation, sparked a sharp decline in ENSG shares earlier this year.

Rosen Law is now organizing a prospective class action to recover losses for those who held the company's securities. Investors are encouraged to contact Phillip Kim at 866-767-3653 or visit the firm’s website to participate in the litigation. The firm, which highlights its history of handling large-scale securities settlements, maintains that shareholders may be eligible for compensation through a contingency fee arrangement, meaning no out-of-pocket costs for participants.